Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.

NCT01052272 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT01052272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01052272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2005
Completion date
November 30, 2010
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes